Venture investment in biopharma and medtech companies continues to trend upward through the third quarter of 2024.
The total amount of capital invested in biopharma therapeutics and discovery platforms remained strong in the third quarter of 2024, maintaining a pace that could result in higher total investment for the year compared to 2023. Medtech followed a similar trend and continues to move in a positive direction with 2024 full-year investments also on track to outpace the total amount of capital invested last year.
Medtech M&A remained active through Q3 2024 compared to prior periods; the total amount of medtech M&A deals through Q3 has already surpassed 2023’s full-year total.
J.P. Morgan’s biopharma therapeutics and medtech licensing reports explore the movement in each sector, offering insight into industry and investment trends that defined the third quarter of 2024 and are shaping the remainder of the year. The reports, powered by DealForma, highlight:
- Deal values in biopharma licensing partnerships
- Trends in deal values for medical devices, diagnostics, digital health therapies and research tools
- Venture investment amounts in therapeutic and platform companies
- The advanced therapies that are seeing healthy investment and dealmaking
- IPO and M&A activity in each sector
Download the full reports to better understand these dealmaking trends and reach out to J.P. Morgan to connect with a Startup Banking expert.
Contributors
Kathryn McDonough
Head of Life Sciences, Innovation Economy, Commercial Banking, J.P. Morgan
Skip Kelly
Head of Healthcare VC Coverage, Commercial Banking, J.P. Morgan
